Share on LinkedInShare on LinkedIn

ARTICLE · 17 AUGUST 2017

Bristol-Myers Squibb: The Aftermath

Morrison Foerster
Morrison Foerster
Contributor
Morrison Foerster

Morrison Foerster

With approximately 1,000 lawyers in 19 offices, Morrison & Foerster is a preeminent global law firm...

View firm profile
Explore more from Morrison Foerster

Last month, the U.S. Supreme Court clarified the scope of specific personal jurisdiction in Bristol-Myers Squibb Co. v. Superior Court of California, San Francisco City.

United StatesLitigation, Mediation & Arbitration

Last month, the U.S. Supreme Court clarified the scope of specific personal jurisdiction in Bristol-Myers Squibb Co. v. Superior Court of California, San Francisco Cty., 137 S. Ct. 1773 (2017) ("BMS"). Mass tort defendants have wasted little time in moving to dispose of claims from nonresident plaintiffs under this ruling.

As previously reported, on June 19, 2017, the Supreme Court decided a longawaited specific jurisdiction question in favor of Bristol-Myers Squibb Co. This case arose when a group of consumers — consisting of 86 California residents and 592 residents from 33 other states — brought tort claims in California state court, alleging injuries from using Plavix, a prescription drug that thins blood and inhibits blood clotting.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from